Tolvaptan: Clinical Trials

25 trials of Tolvaptan, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

22 completed, 2 unknown, 1 terminated. 25 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 225Completed 22, Unknown 2, Terminated 1
Phase 32Completed 1, Unknown 1
Phase 11Completed 1

Follow Tolvaptan: new trials by email Literature Review of Tolvaptan trials Research Report on Tolvaptan

Trials (filtered) newest first · largest first

All 25 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
Tolvaptan 15 MG - Healthy Volunteers
Phase 2UnknownAssistance Publique - Hôpitaux de Paris602019-09-062019-09-10
Tolvaptan-Octreotide LAR Combination in ADPKD
Tolvaptan, Octreotide LAR, Placebo - Autosomal Dominant Polycystic Kidney Disease
Phase 2CompletedMario Negri Institute for Pharmacological Research202018-12-122022-11-03
Effect of the Aquaretic Tolvaptan on Nitric Oxide System
Tolvaptan, Placebo - Autosomal Dominant Polycystic Kidney Disease
Phase 2CompletedRegional Hospital Holstebro182015-02-012017-03-01
A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration
OPC-41061, Placebo - Chronic Renal Failure
Phase 2CompletedOtsuka Pharmaceutical Co., Ltd.1242014-12-012019-10-22
Effect of the Aquaretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA)
15 mg tolvaptan, 30 mg tolvaptan, 45 mg tolvaptan - Nephropathy
Phase 2CompletedRegional Hospital Holstebro152014-03-012017-03-01
A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
tolvaptan - Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
Phase 1 / Phase 2CompletedOtsuka Pharmaceutical Development & Commercialization, Inc.302013-11-012016-05-16
Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites
Standard medical therapy, Tolvaptan, Midodrine - Cirrhosis, Refractory/Recurrent Ascites
Phase 2 / Phase 3CompletedPost Graduate Institute of Medical Education and Research, Chandigarh502013-07-012017-09-19
Open-label Dose-finding Trial of OPC-41061 in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis
OPC-41061 - Chronic Renal Failure
Phase 2CompletedOtsuka Pharmaceutical Co., Ltd.202013-07-012016-01-01
A Phase 2, Multi-center, Open-label, Dose-finding Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of OPC-41061 in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration
OPC-41061 - Chronic Renal Failure
Phase 2CompletedOtsuka Pharmaceutical Co., Ltd.262013-06-012018-08-24
A Multicenter, Open-label, Dose-finding Trial of OPC-41061 to Investigate Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety in Patients With Carcinomatous Edema (Phase 2)
OPC-41061 - Carcinomatous Edema
Phase 2CompletedOtsuka Pharmaceutical Co., Ltd.432012-07-012021-03-18
Effect of the Aquaretic Tolvaptan on Nitric Oxide System (TORA)
Tolvaptan, Placebo - Cardiovascular Diseases, Nephropathy
Phase 2CompletedRegional Hospital Holstebro202012-05-012014-10-09
Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia
Tolvaptan, Placebo - Non-hypovolemic Non-acute Hyponatremia
Phase 2 / Phase 3UnknownJiangsu HengRui Medicine Co., Ltd.2402012-01-012012-01-11
8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Tolvaptan MR, Tolvaptan IR, Placebo - Autosomal Dominant Polycystic Kidney Disease
Phase 2CompletedOtsuka Pharmaceutical Development & Commercialization, Inc.1782011-10-012018-09-27
Tolvaptan for In-hospital Hyponatremia
Tolvaptan, Standard therapy - Hyponatremia
Phase 2TerminatedMario Negri Institute for Pharmacological Research32011-06-012016-12-15
Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD
Tolvaptan MR, Tolvaptan IR - Autosomal Dominant Polycystic Kidney Disease
Phase 2CompletedOtsuka Pharmaceutical Development & Commercialization, Inc.252010-10-012018-06-14
Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Tolvaptan - Autosomal Dominant Polycystic Kidney Disease
Phase 2CompletedOtsuka Pharmaceutical Development & Commercialization, Inc.292010-10-012019-03-05
Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites
Tolvaptan, placebo - Ascites, Hepatic Cirrhosis
Phase 2CompletedOtsuka Beijing Research Institute1802009-04-012012-10-12
A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia
Tolvaptan, Placebo - Hypovolemic Hyponatremia
Phase 2CompletedOtsuka Beijing Research Institute2412008-05-012025-03-25
A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema
OPC-41061 7.5mg, OPC-41061 placebo, OPC-41061 15mg - Cirrhosis
Phase 2CompletedOtsuka Pharmaceutical Co., Ltd.1042007-06-012014-03-14
A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]
OPC-41061 - Autosomal Dominant Polycystic Kidney Disease
Phase 2CompletedOtsuka Pharmaceutical Co., Ltd.172006-04-012018-09-11

Showing 20 of 25. Sign in to see all of them.

Conditions studied

Polycystic Kidney, Autosomal Dominant (7)  ·  Heart Failure (4)  ·  Kidney Diseases (4)  ·  Ascites (3)  ·  Hyponatremia (3)  ·  Kidney Failure, Chronic (3)  ·  Fibrosis (2)  ·  Inappropriate ADH Syndrome (2)  ·  Polycystic Kidney Diseases (2)  ·  Cardiovascular Diseases (1)  ·  Diabetes Insipidus (1)  ·  Edema (1)  ·  Liver Cirrhosis (1)

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc. (8)  ·  Otsuka Pharmaceutical Co., Ltd. (7)  ·  Regional Hospital Holstebro (3)  ·  Mario Negri Institute for Pharmacological Research (2)  ·  Otsuka Beijing Research Institute (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Jiangsu HengRui Medicine Co., Ltd. (1)  ·  Post Graduate Institute of Medical Education and Research, Chandigarh (1)

Countries

Japan (7)  ·  United States (6)  ·  Denmark (4)  ·  China (3)  ·  Italy (2)  ·  Canada (1)  ·  Czechia (1)  ·  France (1)  ·  Germany (1)  ·  Hungary (1)  ·  India (1)  ·  Netherlands (1)  ·  Romania (1)  ·  Spain (1)  ·  Sweden (1)

Top investigators

Frank Czerwiec, M.D., Ph.D. (2)  ·  Katsuhisa Saito (2)  ·  Kyoji Imaoka, Mr (2)  ·  Erling B Pedersen (1)  ·  Feng Gu (1)  ·  Frank Czerweic, MD (1)  ·  Frank Czerwiec, MD, PhD (1)  ·  Frank H Mose, MD, PhD (1)  ·  Giuseppe Remuzzi, MD (1)  ·  James Udelson, MD (1)  ·  Jidong Jia (1)  ·  Junichi Hahimoto, PhD (1)  ·  Minde Zeng (1)

Results publications

PMID 39356039, PMID 21903984, PMID 30180806, PMID 37250503, PMID 17543634, PMID 19007589, PMID 19095138, PMID 24906029, PMID 27614145, PMID 28288570, PMID 28810844, PMID 36754009, PMID 37349694, PMID 37986188

NIH funding

2014 (1), 2017 (1), 2019 (1)